[{"orgOrder":0,"company":"Agenus","sponsor":"Bruno Bockorny","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AGEN1423","moa":"TGF-beta-1\/PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Agenus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agenus \/ Bruno Bockorny","highestDevelopmentStatusID":"8","companyTruncated":"Agenus \/ Bruno Bockorny"}]
Find Clinical Drug Pipeline Developments & Deals for AGEN1423
Details :
AGEN1423 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.